232 related articles for article (PubMed ID: 24390326)
21. One-step multiplex real-time PCR assay to analyse the latency patterns of Epstein-Barr virus infection.
Kubota N; Wada K; Ito Y; Shimoyama Y; Nakamura S; Nishiyama Y; Kimura H
J Virol Methods; 2008 Jan; 147(1):26-36. PubMed ID: 17870188
[TBL] [Abstract][Full Text] [Related]
22. Interferon-γ-inducible protein 16 (IFI16) is required for the maintenance of Epstein-Barr virus latency.
Pisano G; Roy A; Ahmed Ansari M; Kumar B; Chikoti L; Chandran B
Virol J; 2017 Nov; 14(1):221. PubMed ID: 29132393
[TBL] [Abstract][Full Text] [Related]
23. Attenuated immune control of Epstein-Barr virus in humanized mice is associated with the multiple sclerosis risk factor HLA-DR15.
Zdimerova H; Murer A; Engelmann C; Raykova A; Deng Y; Gujer C; Rühl J; McHugh D; Caduff N; Naghavian R; Pezzino G; Capaul R; Zbinden A; Ferlazzo G; Lünemann JD; Martin R; Chatterjee B; Münz C
Eur J Immunol; 2021 Jan; 51(1):64-75. PubMed ID: 32949466
[TBL] [Abstract][Full Text] [Related]
24. Restricted TET2 Expression in Germinal Center Type B Cells Promotes Stringent Epstein-Barr Virus Latency.
Wille CK; Li Y; Rui L; Johannsen EC; Kenney SC
J Virol; 2017 Mar; 91(5):. PubMed ID: 28003489
[TBL] [Abstract][Full Text] [Related]
25. Novel Epstein-Barr virus-like particles incorporating gH/gL-EBNA1 or gB-LMP2 induce high neutralizing antibody titers and EBV-specific T-cell responses in immunized mice.
Perez EM; Foley J; Tison T; Silva R; Ogembo JG
Oncotarget; 2017 Mar; 8(12):19255-19273. PubMed ID: 27926486
[TBL] [Abstract][Full Text] [Related]
26. The human T cell immune response to Epstein-Barr virus.
Landais E; Saulquin X; Houssaint E
Int J Dev Biol; 2005; 49(2-3):285-92. PubMed ID: 15906243
[TBL] [Abstract][Full Text] [Related]
27. PD-1/CTLA-4 Blockade Inhibits Epstein-Barr Virus-Induced Lymphoma Growth in a Cord Blood Humanized-Mouse Model.
Ma SD; Xu X; Jones R; Delecluse HJ; Zumwalde NA; Sharma A; Gumperz JE; Kenney SC
PLoS Pathog; 2016 May; 12(5):e1005642. PubMed ID: 27186886
[TBL] [Abstract][Full Text] [Related]
28. Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state.
Tierney RJ; Steven N; Young LS; Rickinson AB
J Virol; 1994 Nov; 68(11):7374-85. PubMed ID: 7933121
[TBL] [Abstract][Full Text] [Related]
29. MYC Controls the Epstein-Barr Virus Lytic Switch.
Guo R; Jiang C; Zhang Y; Govande A; Trudeau SJ; Chen F; Fry CJ; Puri R; Wolinsky E; Schineller M; Frost TC; Gebre M; Zhao B; Giulino-Roth L; Doench JG; Teng M; Gewurz BE
Mol Cell; 2020 May; 78(4):653-669.e8. PubMed ID: 32315601
[TBL] [Abstract][Full Text] [Related]
30. A novel animal model of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in humanized mice.
Sato K; Misawa N; Nie C; Satou Y; Iwakiri D; Matsuoka M; Takahashi R; Kuzushima K; Ito M; Takada K; Koyanagi Y
Blood; 2011 May; 117(21):5663-73. PubMed ID: 21467545
[TBL] [Abstract][Full Text] [Related]
31. CD8+ T cells retain protective functions despite sustained inhibitory receptor expression during Epstein-Barr virus infection in vivo.
Chatterjee B; Deng Y; Holler A; Nunez N; Azzi T; Vanoaica LD; Müller A; Zdimerova H; Antsiferova O; Zbinden A; Capaul R; Dreyer JH; Nadal D; Becher B; Robinson MD; Stauss H; Münz C
PLoS Pathog; 2019 May; 15(5):e1007748. PubMed ID: 31145756
[TBL] [Abstract][Full Text] [Related]
32. EBV-Encoded Latent Genes.
Kanda T
Adv Exp Med Biol; 2018; 1045():377-394. PubMed ID: 29896676
[TBL] [Abstract][Full Text] [Related]
33. EBV epigenetically suppresses the B cell-to-plasma cell differentiation pathway while establishing long-term latency.
Styles CT; Bazot Q; Parker GA; White RE; Paschos K; Allday MJ
PLoS Biol; 2017 Aug; 15(8):e2001992. PubMed ID: 28771465
[TBL] [Abstract][Full Text] [Related]
34. Soluble factors produced by activated CD4+ T cells modulate EBV latency.
Nagy N; Adori M; Rasul A; Heuts F; Salamon D; Ujvári D; Madapura HS; Leveau B; Klein G; Klein E
Proc Natl Acad Sci U S A; 2012 Jan; 109(5):1512-7. PubMed ID: 22307606
[TBL] [Abstract][Full Text] [Related]
35. Epstein-Barr virus BZLF1 gene, a switch from latency to lytic infection, is expressed as an immediate-early gene after primary infection of B lymphocytes.
Wen W; Iwakiri D; Yamamoto K; Maruo S; Kanda T; Takada K
J Virol; 2007 Jan; 81(2):1037-42. PubMed ID: 17079287
[TBL] [Abstract][Full Text] [Related]
36. Contributions of CTCF and DNA methyltransferases DNMT1 and DNMT3B to Epstein-Barr virus restricted latency.
Hughes DJ; Marendy EM; Dickerson CA; Yetming KD; Sample CE; Sample JT
J Virol; 2012 Jan; 86(2):1034-45. PubMed ID: 22072770
[TBL] [Abstract][Full Text] [Related]
37. An Epstein-Barr Virus (EBV) mutant with enhanced BZLF1 expression causes lymphomas with abortive lytic EBV infection in a humanized mouse model.
Ma SD; Yu X; Mertz JE; Gumperz JE; Reinheim E; Zhou Y; Tang W; Burlingham WJ; Gulley ML; Kenney SC
J Virol; 2012 Aug; 86(15):7976-87. PubMed ID: 22623780
[TBL] [Abstract][Full Text] [Related]
38. Knockout of Epstein-Barr virus BPLF1 retards B-cell transformation and lymphoma formation in humanized mice.
Whitehurst CB; Li G; Montgomery SA; Montgomery ND; Su L; Pagano JS
mBio; 2015 Oct; 6(5):e01574-15. PubMed ID: 26489865
[TBL] [Abstract][Full Text] [Related]
39. Latency pattern of Epstein-Barr virus and methylation status in Epstein-Barr virus-associated hemophagocytic syndrome.
Yoshioka M; Kikuta H; Ishiguro N; Endo R; Kobayashi K
J Med Virol; 2003 Jul; 70(3):410-9. PubMed ID: 12767005
[TBL] [Abstract][Full Text] [Related]
40. Epstein-Barr virus presence in pediatric diffuse large B-cell lymphoma reveals a particular association and latency patterns: analysis of viral role in tumor microenvironment.
Cohen M; De Matteo E; Narbaitz M; Carreño FA; Preciado MV; Chabay PA
Int J Cancer; 2013 Apr; 132(7):1572-80. PubMed ID: 22987474
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]